After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Peter M.

Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disorder characterized by a diverse spectrum of clinical manifestations. Although survival rates among patients with SLE have ...

A common form of lupus is systemic lupus erythematosus. Systemic lupus erythematosus affects the whole body and can attack virtually any part of it, including skin, major organs, hair, muscles ...

However, the bill also includes a 57% cut in funding for the Congressionally Directed Medical Research Programs (CDMRP), which include the Lupus Research Program (LRP) as well as more than 40 other ...

Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy tissue, often affecting the skin, joints, kidneys and nervous system.

For its part, BMS is also investigating Sotyktu as a treatment for other autoimmune diseases including discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE) and Sjögren’s syndrome.

CLE may occur in association with systemic lupus erythematosus (SLE). The most common subtypes are discoid (DLE) and subacute (SCLE), accounting for 80% and 16% of cases, respectively. Both TYK2 ...